Tempramed receives Chinese patent for Vivi Box

Executive Summary

• Tempramed Technologies Ltd. has received a formal patent grant from the China National Intellectual Property Administration for its new product, the "Vivi Box," a multimedication storage box.
• The patent covers key proprietary technologies including thermal insulation and smart monitoring architecture, supporting the company's strategy to expand into scalable, multidose medication storage systems.
• The Vivi Box is scheduled for market launch at the end of 2026, adding to Tempramed's existing portfolio of four currently marketed products.

Key Details

• Patent Grant: Chinese patent application No. 202310499587.4 was formally granted by the China National Intellectual Property Administration.
• Timeline: The patent application was filed on October 24, 2019, and granted on March 17, 2026.
• Product Details (Vivi Box):
  • Described as the company's first-of-its-kind multimedication storage box.
  • Planned market launch: End of 2026.
  • Will add to an existing portfolio of four products already in the market.
• Patent Claims & Technology:
  • Core elements include proprietary thermal insulation and smart monitoring architecture.
  • Features continuous temperature protection during power interruptions or refrigerator temperature fluctuations for several medication devices and vials.
  • Includes portable, all-day travel functionality for secure on-the-go cold storage.
  • Incorporates smart content tracking with cloud-based data integration to support adherence and remote monitoring.
• Strategic Context:
  • The innovation positions the Vivi Box at the intersection of home health, smart refrigeration, and the connected medical device ecosystem.
  • Supports Tempramed's strategy to expand beyond single injection protection into scalable, multidose, and multiformat medication storage systems.
• Recent Milestones:
  • Grant of a similar patent in South Korea.
  • Entry into several distribution agreements.
  • Validation of return on investment model for insurance payers, verified by hundreds of clinicians recommending the existing "Vivi Cap" product.

Notable Quotes

• "The formal grant of our Chinese patent represents a significant milestone in Tempramed's global intellectual property strategy... Securing patent protection in this jurisdiction meaningfully strengthens our position and expands our presence comprehensive product portfolio across Asia." — Ron Nagar, CEO
• "The Vivi Box will add to our existing portfolio of products we already have on the market, with our proprietary technology at the core of all of them. As we continue to build out new product categories and scale our platform, protecting our core innovations remains fundamental to unlocking long-term shareholder value and establishing global leadership in temperature-controlled medication management." — Ron Nagar, CEO